DUBLIN – Aicuris Anti-infective Cures GmbH is pursuing a novel approach to harnessing phage therapy in the fight against antibiotic-resistant infections, by in-licensing from Lysando AG a platform technology that relies on phage-encoded enzymes rather than the infectious particles themselves to lyse pathogenic bacteria. Financial terms were not disclosed, but the deal gives Aicuris exclusive access to Lysando's artilysin platform for pharmaceutical applications.